
|Videos|May 13, 2013
Treating Patients With Chemotherapy and Biotherapy
Author(s)Monica Fradkin, RN, BSN, MPH, OCN
Monica Fradkin, RN, BSN, MPH, OCN, Oncology Nursing Education Coordinator, Yale School of Nursing, Smilow Cancer Hospital at Yale-New Haven, discusses treating patients with chemotherapy and biotherapy.
Advertisement
Monica Fradkin, RN, BSN, MPH, OCN, Oncology Nursing Education Coordinator, Yale School of Nursing, Smilow Cancer Hospital at Yale-New Haven, discusses treating patients with chemotherapy and biotherapy.
Clinical Pearls
Biotherapies are very targeted, Fradkin says, targeting one specific cell type or gene. All biotherapies are often grouped together as hazardous, even though they may not all be. Safety measures still need to be taken to keep patients safe.
- Biotherapy is very targeted, looking at one specific cell type or gene
- Biotherapies are categorized together as hazardous drugs, when they may not all be
- Safety measures need to be kept in place in order to keep patients safe
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
How the Immune System Drives Nerve Growth in TNBC
3
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5



































